Navigation Links
New Irish research sheds light on how aspirin works to reduce cancer deaths
Date:8/14/2014

Researchers have discovered that women who had been prescribed aspirin regularly before being diagnosed with breast cancer are less likely to have cancer that spread to the lymph-nodes than women who were not on prescription aspirin. These women are also less likely to die from their breast cancer.

The study of Irish patients funded by the Irish Health Research Board and Irish Cancer Society and published by the American Association for Cancer Research in the Journal, Cancer Research, analyses records from the National Cancer Registry Ireland (NCRI), and prescription data from the General Medical Service (GMS) pharmacy claims database.

"Our findings suggest that aspirin could play a role in reducing mortality from breast cancer by preventing the cancer spreading to nearby lymph nodes", said Dr Ian Barron, the lead author who carried out the research at Trinity College Dublin, and is now working at Johns Hopkins, USA.

"We analysed data from 2,796 women with stage I-III breast cancer. We found that those women prescribed aspirin in the years immediately prior to their breast cancer diagnosis were statistically significantly less likely to present with a lymph node-positive* breast cancer than non-users. The association was strongest among women prescribed aspirin regularly and women prescribed higher aspirin doses. We now need to establish how and why this is the case".

The findings are consistent with two other major studies. The first is an analysis of cardiovascular trials where pre-diagnostic aspirin** use was associated with a statistically significant reduction in the risk of developing metastases and dying from cancer.

The second is an observation from in vivo breast cancer models, which suggest a possible mechanism by which aspirin may reduce the risk of cancer spreading to other parts of the body.

Professor Kathleen Bennett, a co-author from the Department of Pharmacology & Therapeutics, School of Medicine, Trinity College Dublin said: "Our study was observational and these results do not mean that women should start taking aspirin as a precautionary measure. Aspirin can have serious side effects. We still need to identify exactly how aspirin may prevent breast cancer from spreading to the lymph nodes; which women, or types of breast cancer, are most likely to benefit from taking aspirin; as well as what the optimum doses might be. Research to help answer the next questions is funded by the Irish Cancer Society as part of its first National Collaborative Cancer Research Centre, BREAST-PREDICT".

Dr Graham Love, Chief Executive of the Irish Health Research Board said: "These results have great potential to help improve our understanding of how to increase Irish and global survival rates from breast cancer."


'/>"/>

Contact: Yolanda Kennedy
yokenned@tcd.ie
353-896-3551
Trinity College Dublin
Source:Eurekalert

Related medicine news :

1. Leading Irish scientist speaks on how the mind works to educators at ILLUSION Expo
2. Daniel P. O'Toole and Stephen J. Murphy, of Leading New York Personal Injury Law Firm Block O'Toole & Murphy, LLP, Honored With Selection To "2013 Irish Legal 100".
3. "Rise and Shine: The Jay Demerit Story" Exclusive Showing at Slainte Irish Pub and Restaurant to Beat Cancer
4. DePuy ASR Hip Recall News: Bernstein Liebhard LLP Comments on Irish Health Services Plan to Launch Major Review of Metal-on-Metal Hip Implants
5. Hollywood Star Tom Cruise Presented with Certificate of Irish Heritage
6. Green biased yellow fever swept through Irish Immigrants in 19th century US
7. Scientists detail urgent research agenda to address chronic disease toll
8. ChanTest Announces a Global Campaign to Share New Findings and Developments in Cystic Fibrosis (CF) Research
9. New Research Finds Mesothelioma Surgery Outcomes Can Be Improved, According to Surviving Mesothelioma
10. Ethane Industry 2014 Development Trends in Global & China Regions in a New Study Available at DeepResearchReports.com
11. Researchers identify tests to diagnose invasive aspergillosis with 100 percent accuracy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
Breaking Medicine Technology: